Showing results (631-640 of 645) with videos related to

Sort By:
Pageof 65
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 27, 2021
Burkitt Lymphoma International Prognostic IndexAdam J Olszewski, Lasse H Jakobsen, Graham P Collins, et al.
Resuscitation|April 12, 2026
Effect of Vascular Access Strategy on Long-Term Outcomes in Patients with Out-of-hospital Cardiac Arrest A Randomised Clinical TrialMikael Fink Vallentin, Mathias J Holmberg, Asger Granfeldt, et al.
Resuscitation|May 10, 2025
Intraosseous vs. intravenous access during out-of-hospital cardiac arrest: a Bayesian secondary analysis of a randomised clinical trialMikael Fink Vallentin, Mathias J Holmberg, Asger Granfeldt, et al.
Blood Advances|July 20, 2021
HIV-associated Burkitt lymphoma: outcomes from a US-UK collaborative analysisJuan Pablo Alderuccio, Adam J Olszewski, Andrew M Evens, et al.
Haematologica|February 4, 2021
Outcomes of Burkitt lymphoma with central nervous system involvement: evidence from a large multicenter cohort studyAdam S Zayac, Andrew M Evens, Alexey Danilov, et al.
Blood|July 15, 2020
Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centersAndrew M Evens, Alexey Danilov, Deepa Jagadeesh, et al.
Geburtshilfe Und Frauenheilkunde|February 13, 2026
Diagnosis and Therapy of Endometriosis. Guideline of the DGGG, OEGGG and SGGG (S2k-Level, AWMF Registry No. 015/045, April 2025)Stefanie Burghaus, Sebastian D Schäfer, Karl-Jürgen Bär, et al.
Blood Advances|February 24, 2026
Benefit of rituximab maintenance after first-line bendamustine-rituximab in patients with mantle cell lymphomaYucai Wang, Melissa C Larson, Steven R Hwang, et al.
Blood Advances|December 11, 2025
Benefit of Rituximab Maintenance After First-line Bendamustine-Rituximab in Patients with Mantle Cell LymphomaYucai Wang, Melissa C Larson, Steven R Hwang, et al.
Blood Cancer Journal|April 25, 2026
Mantle cell lymphoma outcomes following sequential first-line bendamustine-rituximab and second-line Bruton's tyrosine kinase inhibitor therapyYucai Wang, Melissa C Larson, Steven R Hwang, et al.
Pageof 65